| __timestamp | Ascendis Pharma A/S | Geron Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 6274000 | 16758000 |
| Thursday, January 1, 2015 | 9415000 | 17793000 |
| Friday, January 1, 2016 | 11504000 | 18761000 |
| Sunday, January 1, 2017 | 13482000 | 19287000 |
| Monday, January 1, 2018 | 25057000 | 18707000 |
| Tuesday, January 1, 2019 | 48473000 | 20893000 |
| Wednesday, January 1, 2020 | 76669000 | 25678000 |
| Friday, January 1, 2021 | 160180000 | 29665000 |
| Saturday, January 1, 2022 | 221227000 | 43628000 |
| Sunday, January 1, 2023 | 264410000 | 69135000 |
| Monday, January 1, 2024 | 284545000 |
Infusing magic into the data realm
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Ascendis Pharma A/S and Geron Corporation, two prominent players, offer a fascinating study in contrasts. From 2014 to 2023, Ascendis Pharma's SG&A expenses surged by over 4,100%, reflecting its aggressive growth strategy. In contrast, Geron Corporation's expenses increased by approximately 310%, indicating a more conservative approach.
Ascendis Pharma's expenses peaked in 2023, reaching nearly four times that of Geron. This trend suggests Ascendis is heavily investing in its operations, possibly to expand its market presence. Meanwhile, Geron's steadier expense growth may point to a focus on maintaining operational efficiency. Understanding these strategies provides valuable insights into how biotech companies balance growth and cost management.
Operational Costs Compared: SG&A Analysis of Merck & Co., Inc. and Geron Corporation
Cost Management Insights: SG&A Expenses for United Therapeutics Corporation and Ascendis Pharma A/S
Cost Management Insights: SG&A Expenses for Intra-Cellular Therapies, Inc. and Ascendis Pharma A/S
Comparing SG&A Expenses: Intra-Cellular Therapies, Inc. vs Geron Corporation Trends and Insights
BioMarin Pharmaceutical Inc. vs Geron Corporation: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Ascendis Pharma A/S or Amneal Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Ascendis Pharma A/S vs Dynavax Technologies Corporation
Comparing SG&A Expenses: Ascendis Pharma A/S vs Xencor, Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Cytokinetics, Incorporated and Geron Corporation
Cost Management Insights: SG&A Expenses for Veracyte, Inc. and Geron Corporation
Cost Management Insights: SG&A Expenses for ACADIA Pharmaceuticals Inc. and Geron Corporation
Cost Management Insights: SG&A Expenses for MorphoSys AG and Geron Corporation